Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Sales and Divestitures (2019 - 2026)

Cytosorbents filings provide 7 years of Gains from Sales and Divestitures readings, the most recent being $65000.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 62.5% to $65000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $65000.0, a 62.5% increase, with the full-year FY2025 number at $65000.0, up 62.5% from a year prior.
  • Gains from Sales and Divestitures hit $65000.0 in Q4 2025 for Cytosorbents, up from $35000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $297169.0 in Q3 2024 to a low of $20000.0 in Q2 2024.
  • Median Gains from Sales and Divestitures over the past 5 years was $63750.0 (2023), compared with a mean of $99601.2.
  • The widest YoY moves for Gains from Sales and Divestitures: up 595.0% in 2025, down 88.22% in 2025.
  • Cytosorbents' Gains from Sales and Divestitures stood at $196525.0 in 2021, then crashed by 77.1% to $45000.0 in 2022, then skyrocketed by 38.89% to $62500.0 in 2023, then tumbled by 36.0% to $40000.0 in 2024, then soared by 62.5% to $65000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $65000.0 (Q4 2025), $35000.0 (Q3 2025), and $139000.0 (Q2 2025) per Business Quant data.